CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
erlotinib hydrochloridedrug
Likely dose
Erlotinib 150 mg orally once daily until disease progressionAI-extracted
Key inclusion· 5
  • ✓Histologically or cytologically confirmed malignant peripheral nerve sheath tumor (malignant schwannoma or neurofibrosarcoma)
  • ✓Unresectable or metastatic disease
  • ✓Measurable disease
  • ✓Age 18 years or older
Key exclusion· 8
  • ✕Known current CNS metastases
  • ✕History of corneal diseases including dry eye syndrome, Sjögren's syndrome, keratoconjunctivitis sicca, exposure keratopathy, or Fuchs' dystrophy
  • ✕Other active corneal disorders
  • ✕Gastrointestinal disease preventing oral medication intake or requiring IV alimentation

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00068367
NCT00068367Phase 2Completed
CompareCT.gov

U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II

SWOG Cancer Research Network·interventional·Posted Sep 11, 2003·Updated Nov 6, 2017

In Brief

A Phase 2 clinical trial evaluating erlotinib hydrochloride for Sarcoma. Completed, enrolled 24 participants across 101 sites.

Detailed Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with unresectable or metastatic malignant peripheral nerve sheath tumor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 11, 2003
Enrollment StartDec 1, 2003
Primary CompletionJul 1, 2007
Study CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 22.8 years ago

Interventions

erlotinib hydrochloridedrug

150 mg per day, daily until disease progression